These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7855615)

  • 21. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
    Oudard S; Levalois C; Andrieu JM; Bougaran J; Validire P; Thiounn N; Poupon MF; Fourme E; Chevillard S
    Anticancer Res; 2002; 22(1A):121-8. PubMed ID: 12017273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
    Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
    Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma.
    Geller JI; Dome JS
    Pediatr Blood Cancer; 2006 Apr; 46(4):527. PubMed ID: 16365852
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance: molecular and clinical aspects.
    Dicato M; Duhem C; Pauly M; Ries F
    Cytokines Cell Mol Ther; 1997 Jun; 3(2):91-9. PubMed ID: 9287248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunochemotherapy of metastatic renal cell carcinoma: report of 28 cases.
    Wang HJ; Chen HX; Li HZ
    Chin Med J (Engl); 2005 Jan; 118(2):172-3. PubMed ID: 15667805
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapeutic indication of interferons for renal cell carcinoma].
    Harano M; Naito S
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
    [No Abstract]   [Full Text] [Related]  

  • 28. Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage.
    Tobe SW; Noble-Topham SE; Andrulis IL; Hartwick RW; Skorecki KL; Warner E
    Clin Cancer Res; 1995 Dec; 1(12):1611-5. PubMed ID: 9815963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of recurrent or metastatic renal cell carcinoma.
    Shah RN; Ahmad T; Eisen TG
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 31. Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling.
    Korkola JE; Kondagunta GV; Reuter VE; Motzer RJ; Chaganti RS
    J Urol; 2007 Apr; 177(4):1264-8; discussion 1268. PubMed ID: 17382702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR as a target for therapy of renal cancer.
    Hudes GR
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):772-4. PubMed ID: 17998894
    [No Abstract]   [Full Text] [Related]  

  • 33. P-glycoprotein expression in squamous cell carcinoma of the oral and maxillofacial region.
    Xie ZJ; Yang XF; Gu ZY; Wu QL
    Chin J Dent Res; 2000 May; 3(1):23-6. PubMed ID: 11314336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
    Pan BF; Nelson JA
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):697-702. PubMed ID: 17009030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy of renal cell carcinoma: 1983-1989.
    Yagoda A
    Semin Urol; 1989 Nov; 7(4):199-206. PubMed ID: 2694257
    [No Abstract]   [Full Text] [Related]  

  • 36. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.
    Gao P; Zhou GY; Guo LL; Zhang QH; Zhen JH; Fang AJ; Lin XY
    Cancer Lett; 2007 Oct; 256(1):81-9. PubMed ID: 17637500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.
    Feller N; Hoekman K; Kuiper CM; Linn SC; Verheul HM; Wolthers BG; Popp-Snijders C; Pinedo HM
    Clin Cancer Res; 1997 Mar; 3(3):389-94. PubMed ID: 9815696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What's new in renal cell carcinoma.
    Meng MV; Nelson H
    Bull Am Coll Surg; 2012 Aug; 97(8):65-6. PubMed ID: 22973751
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
    Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
    Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.